Advertisement
Screener

Cardio Diagnostics Holdings, Inc. (CDIO) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

2.8 / 5 stars · 68/120 Roast Me

Cardio Diagnostics Holdings, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest

Cardio Diagnostics Holdings, Inc. (CDIO) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$1.50 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.

Financial Statements › Income Statement › Net Income

us-gaap:ProfitLoss · last filed 2026-08-07

  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was -$1.50M.
  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$1.79M.
  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$1.71M.
  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-06-30 was -$1.68M.
  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$6.50M.
  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$8.38M.
  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$8.38M.
  • Cardio Diagnostics Holdings, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$4.66M.
Period endNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 1 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month as first filedNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 7 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 monthNet Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month
2026-06-30-$1.50M
10-Q · filed 2026-08-07
-$3.29M
derived: sum of 2 quarters · filed 2026-08-07
2026-03-31-$1.79M
10-Q · filed 2026-08-07
2025-12-31-$6.50M
10-K · filed 2026-03-13
2025-09-30-$1.71M
10-Q · filed 2025-11-12
-$3.40M
derived: sum of 2 quarters · filed 2026-08-07
-$5.03M
derived: sum of 3 quarters · filed 2026-08-07
2025-06-30-$1.68M
10-Q · filed 2026-08-07
-$3.32M
derived: sum of 2 quarters · filed 2026-08-07
2025-03-31-$1.64M
10-Q · filed 2026-08-07
2024-12-31-$8.38M
10-K · filed 2026-03-13
2024-09-30-$1.41M
10-Q · filed 2025-11-12
-$2.70M
derived: sum of 2 quarters · filed 2025-11-12
-$6.86M
derived: sum of 3 quarters · filed 2025-11-12
-$8.25M
derived: sum of 4 quarters · filed 2025-11-12
2024-06-30-$1.29M
10-Q · filed 2025-11-12
-$5.45M
derived: sum of 2 quarters · filed 2025-11-12
-$6.84M
derived: sum of 3 quarters · filed 2025-11-12
-$8.77M
derived: sum of 4 quarters · filed 2025-11-12
2024-03-31-$4.16M
10-Q · filed 2025-11-12
-$5.55M
derived: sum of 2 quarters · filed 2025-11-12
-$7.48M
derived: sum of 3 quarters · filed 2025-11-12
-$11.51M
derived: sum of 4 quarters · filed 2025-11-12
2023-12-31-$1.39M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20
-$3.32M
derived: sum of 2 quarters · filed 2025-03-20
-$7.34M
derived: sum of 3 quarters · filed 2025-03-20
-$8.38M
10-K · filed 2025-03-20
2023-09-30-$1.93M
10-Q · filed 2024-11-13
-$5.96M
derived: sum of 2 quarters · filed 2024-11-13
-$6.99M
10-Q · filed 2023-11-13
-$9.37M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$4.02M
10-Q · filed 2024-11-13
-$5.06M
10-Q · filed 2023-08-14
-$7.43M
derived: sum of 3 quarters · filed 2024-11-13
-$7.23M
derived: sum of 4 quarters · filed 2024-11-13
2023-03-31-$1.03M
10-Q · filed 2024-11-13
-$3.41M
derived: sum of 2 quarters · filed 2024-11-13
-$3.21M
derived: sum of 3 quarters · filed 2024-11-13
-$3.70M
derived: sum of 4 quarters · filed 2024-11-13
2022-12-31-$2.38M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01
-$2.18M
derived: sum of 2 quarters · filed 2024-04-01
-$2.67M
derived: sum of 3 quarters · filed 2024-04-01
-$4.66M
10-K · filed 2024-04-01
2022-09-30$202.27K
10-Q · filed 2022-11-07
-$290.38K
derived: sum of 2 quarters · filed 2022-11-07
-$2.28M
10-Q · filed 2023-11-13
2022-06-30-$492.65K
10-Q · filed 2022-11-07
-$1.13M
10-Q · filed 2023-08-14
2022-03-31-$290.06K
10-Q · filed 2023-05-15
-$222.66K
10-Q · filed 2022-05-12
2021-12-31-$144.84K
10-K · filed 2022-03-31
-$620.45K
10-K · filed 2023-03-31
2021-09-30-$324.00
10-Q · filed 2022-11-07
2021-06-30-$397.00
10-Q · filed 2022-11-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
VOLITIONRX LTD (VNRX)$0.003B-0.64
Q/C TECHNOLOGIES, INC. (QCLS)United States$0.008B-1.93
BIOMERICA INC (BMRA)United States$0.011B
IMMUCELL CORP /DE/ (ICCC)United States$0.091B116.10
Insight Molecular Diagnostics Inc. (IMDX)United States$0.129B-3.90
MYRIAD GENETICS INC (MYGN)United States$0.397B-4.84
Alpha Teknova, Inc. (TKNO)United States$0.500B-18.12
QuidelOrtho Corp (QDEL)United States$0.733B-0.90
ACHIEVE LIFE SCIENCES, INC. (ACHV)United States$0.806B-5.88
Intellia Therapeutics, Inc. (NTLA)United States$1.705B-5.92